Roche Holding AG (SWX: ROG)
Switzerland
· Delayed Price · Currency is CHF | Market Cap | 198.60B |
| Revenue (ttm) | 60.58B |
| Net Income (ttm) | 10.62B |
| Shares Out | 796.79M |
| EPS (ttm) | 13.24 |
| PE Ratio | 18.69 |
| Forward PE | 12.60 |
| Dividend | 9.60 (3.88%) |
| Ex-Dividend Date | n/a |
| Volume | 2,659,072 |
| Open | 243.50 |
| Previous Close | 246.70 |
| Day's Range | 243.10 - 247.80 |
| 52-Week Range | 212.90 - 288.20 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial StatementsNews
Roche-Prothena Partnered Mid-Stage Parkinson's Trial Misses Primary Endpoint, But Cling On Signs Of Clinical Benefits
Prothena and Roche report Phase 2b PADOVA ... Full story available on Benzinga.com
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
An experimental Parkinson’s drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Roche's Parkinson's Drug Candidate Misses Key Goal in Mid-Stage Study
An experimental Parkinson's drug missed its primary goal in a mid-stage trial, Roche said, in what is the second setback this week for candidate treatments for the neurodegenerative condition.
Roche, Prothena miss main goal in mid-stage trial for Parkinson’s drug
Prothena (PRTA) stock gains even as Parkinson's disease therapy developed with Roche (RHHBY) misses primary endpoint in mid-stage trial. Read more here,
Bank of Japan faces more pressure to raise rates in 2025, says David Roche
David Roche, strategist at Quantum Strategy, discusses the Bank of Japan's latest interest rate decision and its outlook in 2025.
Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus
Roche Halts Development of SPK-8011 Amid Strategic Gene Therapy Focus
Roche's Phase IIb study of prasinezumab missed primary endpoint, but suggests possible benefit in early-stage Parkinson's disease
Basel, 19 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in 586 people with early-stage Parkinson's disease, trea...
Genentech's Phase IIb Study of Prasinezumab Missed Primary Endpoint, but Suggests Possible Benefit in Early-Stage Parkinson's Disease
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today results from the Phase IIb PADOVA study investigating prasinezumab in ...
Merck Joins The Weight-Loss Race, Inking $2.01 Billion Deal To Take On Eli Lilly, Pfizer, Roche
Merck threw its hat into the obesity race on Wednesday, inking a deal worth up to $2.01 billion with Hansoh Pharma for its weight-loss drug.
Roche transforms mass spectrometry diagnostics with launch of cobas® Mass Spec solution
Basel, 18 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has received CE mark approval for its cobas® Mass Spec solution including the cobas® i 601 analyser and the first I...
Sangamo surges 24% after Roche ends development of hemophilia A gene therapy
AbbVie to acquire Roche spinout Nimble for $200M upfront
AbbVie (ABBV) has agreed to acquire Roche spinout and psoriasis drug developer Nimble Therapeutics for $200M upfront. Read more here.
Roche's Vabysmo prefilled syringe (PFS) approved in the EU for three retinal conditions that can cause blindness
Basel, 13 December 2024– Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency has approved Vabysmo® (faricimab) 6.0 mg single-dose prefilled syringe (PFS) for use in t...
Roche receives CE Mark for new and updated molecular cobas 6800/8800 systems, enhancing laboratory efficiency and testing capabilities
Basel, 13 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the CE certification of the new cobas® 6800/8800 systems 2.0. The update significantly enhances the efficiency of laborator...
New and updated data for Roche’s fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
Long-term data confirm fixed-duration Columvi and Lunsumio achieve durable remissions beyond the end of treatment, with real-world data suggesting reduced treatment-related travel burden due to less f...
New and updated data for Roche's fixed-duration Columvi and Lunsumio at ASH 2024 reinforce their potential to improve outcomes for people with lymphoma
Basel, 10 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new and updated data from its industry-leading CD20xCD3 T-cell-engaging bispecific antibody programme were presented a...
New and Updated Data for Genentech's Fixed-Duration Columvi and Lunsumio at ASH 2024 Reinforce Their Potential to Improve Outcomes for People With Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new and updated data from its industry-leading CD20xCD3 T-cell-e...
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash
Basel, 9 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of Poseida Therapeutics, Inc. (Poseid...
Five-Year Results Confirm Genentech's Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX stud...
Five-year results confirm Roche's Polivy combination therapy as new standard of care for previously untreated aggressive lymphoma
Basel, 8 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from a five-year follow-up of the pivotal phase III POLARIX study evaluating Polivy® (polatuzumab vedotin) in combinati...
Roche (RHHBY) Awaits FDA Decision on Glofitamab for Lymphoma Treatment
Roche (RHHBY) Awaits FDA Decision on Glofitamab for Lymphoma Treatment
FDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Basel, 5 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA...
FDA Accepts Supplemental Biologics License Application for Genentech's Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Gypto Pharma and Roche celebrate the successful completion of the first phase of transferring biotechnology and manufacturing a biologic drug to treat liver cancer using Swiss technology
This milestone marks a significant contribution to Egypt's transformation from a technology user into a technology leader
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics Inc. (NASDAQ: OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients . In the NORSE EIGHT trial, ONS...